Takeda Gmbh

Heidelberg Pharma Research Gmbh

Heidelberg Pharma Gmbh

Andreas Pahl

Sarvesh S Patel

Thomas Maier

Beate Schmidt

Dieter Flockerzi

Heiko Bernsmann

Ewald Benediktus

Alexander Sudau

Ulrich Kautz

Werner Simon

Degenhard Marx

Martin Viertelhaus

Hermann Tenor

Ragna Hussong

Christian Lutz

Rolf-Peter Hummel

Torsten Hechler

Christian Hesslinger

Christoph Müller

Stefan Fischer

Torsten Dunkern

Michael Kulke

Josef Stadlwieser

Matthias Mueller

Olaf Nimz

Christof Zitt

Jan Anderl

Christoph Mueller

Hiteshkumar D Jain

Rainer Boer

Manuela Hessmann

Barbara Korsak

Francesca Gallo

Anikó Pálfi

Harald Ohmer

Alexander Mann

Angelika Hoffmeyer

Ashish Keche

Manojkumar Tiwari

Arati Prabhu

Sandip Gavade

Mahindra Makhija

Christiane Praechter

Simone Hartung

Hans Christof Holst

Tobias Kanacher

Christoph MÜLLER

Matthias MÜLLER

The present application relates to conjugates comprising an amatoxin a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking said amatoxin and said CD37-binding moiety. The invention further relates to the synthesis of said conjugates. In addition, the invention relates to a pharmaceutical composition comprising such conjugate for use in the treatment of immune cell-, particularly B-cell and/or lymphoma associated diseases and/or malignancies.

B-lymphocyte specific amatoxin antibody conjugates

The present application relates to humanized and/or deimmunized antibodies, antibody fragments or antibody derivatives that bind to Prostate Specific Membrane Antigen (PSMA) and methods for using said antibodies, antibody fragments or antibody derivatives in the treatment of prostate cancer and other neoplastic as well as neurological diseases.

Humanized antibodies against PSMA

The invention relates to a PSMA-targeting conjugate comprising (a) an amatoxin; (b) a small molecule PSMA-targeting moiety; and (c) optionally a linker linking said amatoxin and said small molecule PSMA-targeting moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate.

PSMA-targeting amanitin conjugates

The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6'-deoxy position; and (ii) an amino acid 8 with an S-deoxy position; (b) a BCMA-binding moiety comprising (i) the variable domains of humanized antibody J22.9-ISY, and (ii) a heavy chain constant region comprising a D265C mutation; and (c) a protease-cleavable linker linking said amatoxin and said target-binding moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate, particularly for use in the treatment of multiple myeloma.

Amanitin antibody conjugates

The invention relates to conjugates comprising amatoxins and antibodies, in particular amatoxins linked to antibodies comprising specific cysteine residues.

Amatoxin-antibody conjugates

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase and are useful for treating or preventing idiopathic pulmonary lung fibrosis.

Methylpyrrolopyrimidinecarboxamides

The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.

EP2 receptor agonists

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

The compounds of Formula (I), wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

Methylpyrrolopyridinecarboxamides

Growing community of inventors

Ahrensburg, Germany

Andreas Pahl